Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Radiother. 2003 Aug;7(4):254-65.

[Chemoradiation in pancreatic carcinoma].

[Article in French]

Author information

1
Département de radiothérapie-oncologie, centre hospitalier Lyon-Sud, 69495 cedex, Pierre-Bénite, France.

Abstract

Prognosis of pancreatic carcinoma remains poor, with one-year and five-year overall survival rates of 20 and 5% respectively. Only 5 to 15% of patients present with tumors amenable to resection. Long-term (5 years) survival after curative resection is less than 20%, and the median survival is about 12 months. This paper updates recent trends about concomitant chemoradiation. At first, a review of the studies on adjuvant chemoradiation after surgery is proposed. Then, indications of preoperative chemoradiation for patients with localized resectable adenocarcinoma are discussed. The last part concerns the most important and recent studies about chemoradiation in locally advanced pancreatic cancer, either with 5-fluoro-uracile or based on new drugs like gemcitabine.

PMID:
12914858
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center